Metastatic NSCLC with G719X/S781I EGFR-mutations with acquired BRAF V600E mutation - response to Osimertinib, Dabrafenib and Trametinib

被引：0
|
作者：
Urbanska, E. M. [1 ]
Sorensen, J. B. [1 ]
Melchior, L. C. [1 ]
Santoni-Rugiu, E. [1 ]
机构：
[1] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
acquired BRAF V600E; uncommon EGFR mutations; Osimertinib; Dabrafenib; Trametinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-06
引用
收藏
页码：S642 / S642
页数：1
相关论文
共 43 条
  • [21] Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
    Wang, Wei
    Smith, Jessica Louise
    Carlino, Matteo Salvatore
    Burmeister, Bryan
    Pinkham, Mark Blayne
    Fogarty, Gerald Blaise
    Christie, David Robert Harry
    Estall, Vanessa
    Shackleton, Mark
    Clements, Arthur
    Wolfe, Rory
    Le Thi Phuong Thao
    Paton, Elizabeth Jane
    Steel, Victoria
    Williams, Narelle Catherine
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 30 : 95 - 99
  • [22] Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation
    Yagami, Yuri
    Nakahara, Yoshiro
    Manabe, Hideaki
    Yamamoto, Hiroki
    Otani, Sakiko
    Sato, Takashi
    Igawa, Satoshi
    Kubota, Masaru
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    ONCOTARGETS AND THERAPY, 2022, 15 : 1369 - 1374
  • [23] Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma
    Wang, T. W.
    Smith, J. L.
    Carlino, M.
    Burmeister, B.
    Pinkham, M. B.
    Fogarty, G. B.
    Christie, D.
    Estall, V.
    Shackleton, M.
    Wolfe, R.
    Phuong, T. L. T.
    Paton, E. J.
    Steel, V.
    Williams, N. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S133 - S134
  • [24] Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
    Mendivil, Alberto A.
    Tung, Paul K.
    Bohart, Randy
    Bechtol, Karen
    Goldstein, Bram H.
    GYNECOLOGIC ONCOLOGY REPORTS, 2018, 26 : 41 - 44
  • [25] MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E
    Tan, Xiang
    Wu, Zuotao
    Chen, Mingwu
    ONCOTARGETS AND THERAPY, 2024, 17 : 307 - 312
  • [26] EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAF V600E mutation: a multi-center real-world experience in China
    Yang, Wenyue
    Feng, Xiangran
    Ni, Jian
    Zhang, Xin
    Yu, Hui
    Wu, Xianghua
    Wang, Huijie
    Zhao, Xinmin
    Hu, Zhihuang
    Yu, Bo
    Zhang, Yao
    Lin, Ying
    Xiang, Yi
    Wang, Jialei
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3500 - 3512
  • [27] Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.
    Abdulla, Diana S. Y.
    Scheffler, Matthias
    Kobe, Carsten
    Persigehl, Thorsten
    Schmidt, Matthias
    Fassunke, Jana
    Merkelbach-Bruse, Sabine
    Michels, Sebastian Yves Friedrich
    Nogova, Lucia
    Koleczko, Sophia
    Fischer, Rieke Nila
    Riedel, Richard
    Drzezga, Alexander
    Buettner, Reinhard
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
    Atreya, Chloe Evelyn
    Van Cutsem, Eric
    Bendell, Johanna C.
    Andre, Thierry
    Schellens, Jan H. M.
    Gordon, Michael S.
    McRee, Autumn Jackson
    O'Dwyer, Peter J.
    Muro, Kei
    Tabernero, Josep
    van Geel, Robin
    Sidhu, Roger
    Greger, James G.
    Rangwala, Fatima A.
    Motwani, Monica
    Wu, Yuehui
    Orford, Keith W.
    Corcoran, Ryan Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
    Puzanov, Igor
    Callahan, Margaret K.
    Linette, Gerald P.
    Patel, Sapna Pradyuman
    Luke, Jason J.
    Sosman, Jeffrey Alan
    Wolchok, Jedd D.
    Hamid, Omid
    Minor, David R.
    Orford, Keith W.
    Hug, Bruce A.
    Ma, Bo
    Matthys, Gemma M.
    Hoos, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
    Igor Puzanov
    Journal of Translational Medicine, 13 (Suppl 1)
12345